- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02809456
Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients
June 22, 2016 updated by: Szu-Yuan Wu, Taipei Medical University WanFang Hospital
This project will test the effect of nicorandil to mitigate the lung damage that can occur as a side effect of radiation therapy for lung cancer.
Thousands of veterans develop lung cancer every year, and are treated by radiation therapy.
Studies of lung radiation injury in laboratory animals show that with nicorandil, investigators can significantly reduce the severity of lung fibrosis and heart toxicity.1,2
Nicorandil is FDA approved and in common use for treatment of angina.
These studies will advance that work to human use.
Successful mitigation of lung radiation damage and heart toxicity will improve the quality of life in veterans and non-veterans who are treated for lung cancer by radiation, and may also improve cure rates of radiation therapy for lung cancer.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or cytologically-proven NSCLC; mixed histology with small cell lung carcinoma (SCLC) component not allowed
- Patients with stage II - IV NSCLC who received at least 54 Gy of total planned thoracic radiation dose will be eligible; patients must have received at least one cycle of chemotherapy concurrently during the course of thoracic radiation; regimens allowed are platinum combinations with either etoposide or a taxane regardless of histology subtype; platinum with pemetrexed for patients with nonsquamous NSCLC only; patients with oligometastatic stage IV cancer are eligible if they have received only one line of systemic therapy for their stage IV cancer prior to the concurrent chemoradiation phase
- Patient must have had a CR/PR/SD, 4-6 weeks after completing last fraction of chemotherapy / radiation therapy.
- Eastern Cooperative Oncology Group (ECOG) performance score 0-2 at the time of randomization
- Absolute neutrophil count (ANC) >= 1,500/uL
- Platelet count >= 100,000/uL
- Hemoglobin >= 9 g/dL
- Total bilirubin =< 1.5 times upper limit of normal (ULN) OR direct bilirubin normal (per institute standards)
- Aspartate aminotransferase (AST) =< 1.5 x ULN; alanine aminotransferase (ALT) and AST =< 3 x ULN is acceptable if there is liver metastasis
- Fertile patients must use adequate contraception
Exclusion Criteria:
- Whole-brain radiotherapy (WBRT) < 14 days from the anticipated start of nicorandil/placebo administration
- Unable to start nicorandil/placebo treatment between 4 - 6 weeks after completing the last dose of thoracic radiation
- Active untreated brain or leptomeningeal metastases; in patients with treated central nervous system (CNS) metastases, eligible if symptoms controlled for at least 4 weeks; dexamethasone allowed if total daily dose does not exceed 2 mg
- Major injuries or surgery (e.g., craniotomy) < 28 days from the start of nicorandil/placebo administration; wound should be healed prior to starting therapy
- Second malignancies are allowed as long as the disease does not require active treatment with concomitant systemic cytotoxic chemotherapy, investigational or biologic therapy (e.g., anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] or human epidermal growth factor receptor 2 [HER2] monoclonal antibodies); hormone-related therapies (e.g., gonadotrophin releasing hormone (LHRH) agonists, tamoxifen, etc.) are allowed
- Concurrent uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would increase the risk associated with study participation and/or limit compliance with study requirements
- Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher proteinuria
- Systemic therapy or investigational agent administered < 28 days prior to treatment with nicorandil
- Pregnancy or breast feeding; female patients with child-bearing potential must have a negative pregnancy test (beta-human chorionic gonadotropin [B-HCG] test in urine or serum) prior to commencing study treatment
- Creatinine > 1.5 x ULN or creatinine clearance levels (CrCL) < 45 mL/min
- Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
- acute myocardial infarction within 2 weeks before percutaneous coronary intervention
- contraindications to treatment with nicorandil (allergy, glaucoma, digestive ulcer, is currently taking phosphodiesterase-5 inhibitor)
- bypass restenosis
- PCI history
- hypotension
- impaired liver function
- renal insufficiency requiring hemodialysis
- pregnancy
- connective tissue disease
- life expectancy ≤ 12 months
- left main coronary artery disease
- bypass graft lesion and lesions unsuitable for OCT
- unwillingness or inability to provide informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Nicorandil
Beginning 4-6 weeks during radiation therapy, patients receive nicorandil is given during radiotherapy interval, 5mg each time, 3 times daily oral.
Treatment repeats after completion of radiation therapy in the absence of disease progression or unacceptable toxicity.
|
oral intake
Other Names:
|
ACTIVE_COMPARATOR: observation
regular radiotherapy as our protocol
|
oral intake
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The rate of symptomatic radiation pneumonitis in patients with unresectable Stage II/III/ oligometastatic IV non-small cell lung carcinoma (NSCLC) who completed chemoradiation followed by nicorandil or not
Time Frame: Up to 2.5 years post-treatment
|
Up to 2.5 years post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The quality of life (QOL) questionnaire
Time Frame: Baseline up to 2.5 years post-treatment
|
Baseline up to 2.5 years post-treatment
|
Biomarker analysis such as TGF-β, Serum surfactant proteins-A & -D, MMP1 and MMP7
Time Frame: Up to 97 days post-treatment
|
Up to 97 days post-treatment
|
The overall survival in patients who received nicorandil versus observation
Time Frame: Up to 2.5 years post-treatment
|
Up to 2.5 years post-treatment
|
Radiation pneumonitis (RP) score in patients who received nicorandil versus observation
Time Frame: Baseline up to 2.5 years post-treatment
|
Baseline up to 2.5 years post-treatment
|
The composite index (based on PFT, RP score and QOL) at the end of active treatment and 6 months after completion of treatment between patients who received nicorandil versus observation.
Time Frame: Baseline up to 2.5 years post-treatment
|
Baseline up to 2.5 years post-treatment
|
Responses rates
Time Frame: Up to 2.5 years post-treatment
|
Up to 2.5 years post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2016
Primary Completion (ANTICIPATED)
July 1, 2019
Study Completion (ANTICIPATED)
December 1, 2019
Study Registration Dates
First Submitted
June 9, 2016
First Submitted That Met QC Criteria
June 21, 2016
First Posted (ESTIMATE)
June 22, 2016
Study Record Updates
Last Update Posted (ESTIMATE)
June 23, 2016
Last Update Submitted That Met QC Criteria
June 22, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Wounds and Injuries
- Lung Diseases, Interstitial
- Lung Injury
- Radiation Injuries
- Pneumonia
- Radiation Pneumonitis
- Physiological Effects of Drugs
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Micronutrients
- Vitamins
- Vitamin B Complex
- Nicorandil
Other Study ID Numbers
- N201508038
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Radiation Pneumonitis
-
Instituto Nacional de Cancerologia de MexicoNational Council of Science and Technology, MexicoCompletedRadiation; Adverse Effect, PneumonitisMexico
-
Xinqiao Hospital of ChongqingRecruiting
-
Beijing Continent Pharmaceutical Co, Ltd.Shanghai Genomics, Inc.; GNI-EPS Pharmaceuticals, Inc. (GNI Group)Unknown
-
Huazhong University of Science and TechnologyHubei Cancer Hospital, Tongji Medical College, Huazhong University of Science... and other collaboratorsRecruitingRadiation PneumonitisChina
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Huazhong University of Science and TechnologyRecruiting
-
Meshalkin Research Institute of Pathology of CirculationRecruitingBreast Neoplasms | Radiation Pneumonitis | Radiation Induced Fibrosis | Radiation PneumoniaRussian Federation
-
Hubei Cancer HospitalRecruiting
-
VA Office of Research and DevelopmentCompleted
-
Xinqiao Hospital of ChongqingCompletedRadiation Pneumonitis | EndostatinChina
Clinical Trials on Nicorandil
-
Yonsei UniversityGE HealthcareCompleted
-
National Cerebral and Cardiovascular CenterCompletedAcute Myocardial InfarctionJapan
-
Peking University Third HospitalCompletedCoronary Artery DiseaseChina
-
Merck KGaA, Darmstadt, GermanyWithdrawn
-
Ahmed Abdel Nasser Abdel RadyNot yet recruiting
-
Fudan UniversityRecruitingST Elevation Myocardial Infarction | Percutaneous Coronary InterventionChina
-
Zhang Ying QianUnknown
-
Guy's and St Thomas' NHS Foundation TrustActive, not recruitingCritical IllnessUnited Kingdom
-
Sejong General HospitalUnknownCoronary Artery Disease | Heart Failure With Reduced Ejection FractionKorea, Republic of
-
Seoul National University HospitalSeoul National University Boramae Hospital; Keimyung University Dongsan Medical... and other collaboratorsUnknownMyocardial Ischemia | Coronary Artery DiseaseKorea, Republic of